Conflict of interest.None of the authors have any conflict of interest to declare, financial or otherwise. No financial or other support was received for the study.Background.The aim of the study was to assess changes in macular thickness after trabeculectomy in respect to the use of 5-fluorouracil (5-FU) as well as to analyse possible associations between the postoperative changes in macular thickness and intraocular pressure (IOP).Materials and methods.The prospective observational study included 106 eyes (100 patients) with glaucoma who underwent trabeculectomy with or without 5-FU. Subsequently 5-FU needling was performed if failure of the filtrating bleb occurred. Macular thickness and the IOP were evaluated before, one week, and six months after the surgery. The mean and sectoral macular thickness was assessed using spectral domain optical coherence tomography.Results.The mean (±SD) IOP reduced from 27.71 (±6.88) mmHg at baseline to 18.3 (±8.1) mmHg one week (p < 0.001) and 15.1 (±7.6) mmHg six months (p < 0.001) after trabeculectomy. One week postoperatively, the mean macular thickness increased from 285.19 (±15.98) μm to 288.9 (±16.31) μm (p < 0.001); macular thickening was significant in all subfields (p < 0.001) and correlated positively with IOP reduction (rho = 0.312, p = 0.001 for central subfield). After six months, macula remained thicker only at the central and inner nasal subfields (p < 0.05). The changes in macular thickness were not affected by the use of 5-fluorouracil.Conclusions.Trabeculectomy may induce a slight macular thickening which is more pronounced in the early postoperative period. The IOP reduction plays an important role in this process and is associated with thicker postoperative macula. However, the use of adjunctive 5-FU has no influence on macular thickness after glaucoma surgery despite its potential hypotonic, inflammatory and cytotoxic effects.

Both I-Care and Tono-Pen tonometers overestimated IOP compared with the GAT values. Either the I-Care or Tono-Pen tonometer could be used instead of GAT because there was no significant difference between their results. Higher CCT values (>555 µm) were associated with overestimated IOP values.

Purpose The aim of the study was to assess changes of macular thickness after trabeculectomy and compare them in respect to the usage of preoperative prostaglandins and status of diabetes mellitus. Methods The prospective observational study included 93 glaucomatous eyes (90 patients) that underwent trabeculectomy. 81 (87.1%) patients were on prostaglandins treatment preoperatively. 5 (5.38%) patients had type 2 diabetes. The foveal and sectoral macular thicknesses were measured preoperatively, 1 week, 6 months and 12 months after the surgery using spectral domain optical coherence tomography. Retinal thickness was compared across the follow‐up visits and in respect to the preoperative use of prostaglandins and diabetes. Results There was a reduction in mean ± SD intraocular pressure of 18.5 ± 8.6mmHg 1 week, 15.4 ± 7.9 mmHg 6 months and 14.4 ± 8.3 mmHg 12 months after trabeculectomy (p < 0.001). 1 week postoperatively retinal thickening was observed in all macular subfields (p < 0.001); the central macular thickness increased from 267.23 ± 19.20 μm at baseline to 271.12 ± 19.59 μm. 6 months postoperatively macula remained slightly thicker in central, nasal, inner superior and outer temporal sectors (2.10 ± 5.97 μm, p < 0.001 in central subfield). 12 months after trabeculectomy retina showed thinning in the outer nasal and superior subfields (‐3.54 ± 8.57 μm; ‐1.94 ± 7.02; p < 0.01, respectively). There were no differences in the changes of macular thickness when compared in respect to preoperative prostaglandins (p > 0.05). The retinal changes did not differ between diabetic and nondiabetic patients (p > 0.05). Conclusions Trabeculectomy induced mild macular thickening, more pronounced in the early postoperative period. Neither diabetes nor the use of prostaglandins before surgery had impact on these changes regardless their potency to increase vascular permeability.

Purpose To report two cases of Purtscher‐like retinopathy associated with acute pancreatitis. Methods Retrospective analysis of two cases of Purtscher‐like retinopathy associated with acute pancreatitis. Fluorescein angiography (FAG), retinal photography, laboratory tests, computer tomography (CT) were analyzed. Results 2 cases were identified in a period from 2007 to 2013. The first, 57 y.o patient with a history of recently treated acute pancreatitis, was referred to clinic 2 weeks after visual impairment. Visual acuity (VA) was 0,3 in the right eye and 0,25 in the left eye. FAG revealed prolonged arterio‐venous passage time, enlarged foveal avascular zone (FAZ), fluorescein blockage temporal to optic nerve disc due to soft exudates. Patient was treated with systemic steroids intravenously. VA improved to 1,0 after 9 days of treatment. The second, 39 years old patient was referred to our clinic 3 days after visual impairment. At the time of hospitalization despite patients normal vital signs, laboratory tests and CT revealed acute pancreatitis and reactive hepatitis. VA was hand motion in the right eye and 0,01 in the left eye. FAG showed large FAZ and evidence of leakage from vessels in the late phase. After treatment with intravenous steroids, VA improved to counting fingers at 30 cm in the right eye and 0,03 in the left eye. Conclusion Prognosis of Purtscher‐like retinopathy may depend on systemic disease severity, VA in early stages and the presence of macular ischemia. Pancreatitis‐associated retinopathy is rare and there are no evidence‐based therapeutic recommendations.